Comparing the current results to its competitors, Intercept Pharmaceuticals Inc reported Revenue increase in the 3 quarter 2023 by 14.44 % year on year. The sales growth was above Intercept Pharmaceuticals Inc 's competitors' average revenue growth of 0.93 %, achieved in the same quarter.
Intercept Pharmaceuticals inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 90.42 %
May 9, 2024
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that primarily affects middle-aged women. With limited treatment options available, the need for innovative therapies is pressing. In this article, we present a comprehensive overview of the recent advancements in the understanding and treatment of PBC, as showcased in the outstanding research and data presented at the Digestive Disease Week (DDW) 2024 conference.Intercept Pharmaceuticals Unveils Exciting New Data:Intercept Pharmaceuticals, a biopharmaceutical company dedicated to developing therapeutics for rare liver diseases, unveiled five compelling abstracts related to PBC at the DDW 2024 conference. These abstracts highlight signif...
Publicly Traded Peers of Intercept Pharmaceuticals inc
Genfit S a Share Performance
+14.12%
30 Days
Genfit S a
Profile
Genfit S has a business model centered around the research, development, and commercialization of drugs for the treatment of chronic liver diseases. They aim to create therapeutic solutions that address unmet medical needs in the field of hepatology by leveraging their expertise and innovative approaches. Their focus lies in advancing clinical programs, securing partnerships, and ultimately bringing their products to market to improve patient outcomes.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Astria Therapeutics Inc's business model centers around developing and commercializing innovative therapeutics for various diseases and medical conditions.
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
Sources:
Intercept Pharmaceuticals inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Intercept Pharmaceuticals inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
